| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Probable G-protein coupled receptor 88, Striatum-specific G-protein coupled receptor, GPR88, STRG |
| Entrez GeneID | 54112 |
| WB Predicted band size | 40.2kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This GPR88 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 325-352 amino acids from the C-terminal region of human GPR88. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于GPR88抗体的代表性文献摘要示例(注：文献信息为示例性内容，非真实存在)：
1. **"Development of a specific antibody for GPR88 and its expression profiling in mouse brain"**
*作者：Smith A, et al.*
摘要：本研究开发了一种高特异性兔源多克隆GPR88抗体，并通过Western blot和免疫组化验证其在纹状体中的选择性表达，证实GPR88在纹状体神经元中的富集分布。
2. **"GPR88 as a potential biomarker in schizophrenia: Antibody-based detection in postmortem brain tissues"**
*作者：Chen L, et al.*
摘要：利用商业化GPR88抗体分析精神分裂症患者脑组织，发现前额叶皮层中GPR88蛋白水平显著降低，提示其可能参与突触可塑性调节及疾病病理机制。
3. **"Validation of a novel monoclonal anti-GPR88 antibody for flow cytometry applications"**
*作者：Kimura T, et al.*
摘要：报道一种新型小鼠单克隆抗体的开发与验证，该抗体适用于流式细胞术检测转染细胞系中GPR88膜表面表达，为药物筛选提供可靠工具。
4. **"GPR88 antibody-guided mapping of receptor distribution in primate basal ganglia"**
*作者：Massart R, et al.*
摘要：通过免疫荧光共定位技术，系统描绘GPR88在非人灵长类基底神经节多巴胺能通路中的特异性表达模式，支持其在运动调节中的潜在功能。
(注：以上文献为虚构示例，实际引用需查询PubMed等数据库获取真实研究。)
GPR88 (G protein-coupled receptor 88) is an orphan receptor belonging to the rhodopsin-like class of G protein-coupled receptors (GPCRs). It is predominantly expressed in the brain, particularly in the striatum, a region critical for motor control, reward, and decision-making. Its restricted localization suggests a specialized role in modulating dopaminergic and glutamatergic signaling pathways. Although its endogenous ligand remains unidentified, GPR88 is implicated in neuropsychiatric disorders, including schizophrenia, addiction, and depression, based on genetic association studies and animal models. GPR88 knockout mice exhibit hyperactivity, altered emotional responses, and cognitive deficits, further linking it to neural circuit dysregulation.
Antibodies targeting GPR88 are essential tools for studying its expression, localization, and function. Due to the receptor’s intracellular loops and transmembrane topology, developing specific antibodies has been challenging. Most commercially available GPR88 antibodies are raised against synthetic peptides corresponding to extracellular N-terminal or intracellular C-terminal regions. These antibodies are validated for techniques like immunohistochemistry, Western blotting, and immunofluorescence. However, cross-reactivity with unrelated proteins has been reported, necessitating careful validation using knockout controls. Recent studies utilize GPR88 antibodies to explore its role in striatal neuron subtypes and its potential as a therapeutic target for neurological disorders. Ongoing research aims to unravel its signaling mechanisms and ligand interactions, which could unlock novel treatment strategies.
×
